Kolexia
Crouzet Laurence Oncologie médicale
Crouzet Laurence
Oncologie médicale
Centre Eugène Marquis
Rennes, France
67 Activités
0 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Carcinomes Tumeurs du sein Néphrocarcinome Carcinome hépatocellulaire Métastase tumorale Tumeurs du foie Diarrhée Tumeurs du cerveau Tumeurs de la prostate

Collaborateurs

Voir plus
Laguerre Brigitte
Laguerre Brigitte
Centre Eugène Marquis, Rennes, France
Perrin Christophe
Perrin Christophe
Centre Eugène Marquis, Rennes, France
Brunot Angelique
Brunot Angelique
Centre Eugène Marquis, Rennes, France
De La Motte Rouge Thibault
De La Motte Rouge Thibault
Centre Eugène Marquis, Rennes, France

Industries

Voir plus
Janssen
10 collaboration(s)
Dernière en 2023
Ipsen
5 collaboration(s)
Dernière en 2023
Bayer
3 collaboration(s)
Dernière en 2023
Pfizer
3 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
STARTER: A National, Multicenter, Phase III Randomized Controlled Trial to Assess the Impact of a One-year Supervised Physical Activity Program to Reduce Long-term Cancer-related Fatigue in Metastatic Testicular Germ Cell Tumor Patients
Essai Clinique (Centre Léon-Bérard)   20 février 2024
PACPAC-EPOC: Phase IV Study Comparing Humeral or Thoracic Implantation of an Central Veinous Access by an Implantable Venous Access Device in Patients With Solid Tumors Requiring Intravenous Chemotherapy
Essai Clinique (Centre Eugène Marquis)   06 février 2024
Plasma-based analysis of ERBB2 mutational status by multiplex digital PCR in a large series of patients with metastatic breast cancer.
Molecular oncology   29 janvier 2024
736P Residual masses after salvage chemotherapy in men with metastatic seminoma: The Semi-ResMass multicenter retrospective study
Abstract Book of the ESMO Congress 2023, 20 - 24 October 2023.   01 octobre 2023
MOIO: Randomized Phase III Trial of Standard Immunotherapy (IO) by Checkpoint Inhibitors, Versus Reduced Dose Intensity of IO in Patients With Metastatic Cancer in Response After 6 Months of Standard IO
Essai Clinique (Unicancer)   29 août 2023
OSCAR: Systemic Oxaliplatin or Intra-arterial Chemotherapy Combined With LV5FU2 +/- Irinotecan and an Target Therapy in First Line Treatment of Metastatic Colorectal Cancer Restricted to the Liver
Essai Clinique (Fédération Francophone de Cancérologie Digestive)   16 août 2023
TALASUR: TALazoparib and Avelumab as Maintenance Therapy in Platinum-Sensitive Metastatic or Locally Advanced URothelial Carcinoma: A Single-arm Phase 2 Trial
Essai Clinique (Pfizer)   31 juillet 2023
HER2CLIMB: Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib vs Placebo in Combination With Capecitabine and Trastuzumab in Patients With Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma
Essai Clinique (Seagen)   26 juillet 2023
ADT +/- Darolutamide in de Novo Metastatic Prostate Cancer Patients With Vulnerable Functional Ability (PEACE6-Vulnerable): A Double-blind Randomised Phase III Trial Evaluating the Efficacy of ADT +/- Darolutamide in de Novo Metastatic Prostate Cancer Patients With Vulnerable Functional Ability and Not Elected for Docetaxel or Androgen Receptor Targeted Agents
Essai Clinique (Bayer)   10 mai 2023
Development of sensitive and robust multiplex digital PCR assays for the detection of ESR1 mutations in the plasma of metastatic breast cancer patients.
Clinica chimica acta; international journal of clinical chemistry   25 avril 2023